Thirty-One Days to List Your Idle Reactor

The Office of Management and Budget asked American chemical manufacturers a question on Friday that Washington has never put this plainly.

Which of your reactors are sitting idle, what do they make, and what would it cost to start them.

That is the ask. The request for information at 91 FR 60983 is market research, run out of the Made in America Office, and it wants "new and unused (idle) domestic, U.S.-based, and near shore production capabilities" for finished dose forms, active ingredients and key starting materials tied to the ASPR 86 list of essential medicines.

Responses close October 26. Thirty-one days from publication, and the policy chain behind the question has been running for 408 of them (chart below).

"Price per unit needed to operate at full capacity."

That line is field seven of nine in the idle-capacity section. We will come back to it, because it is the field that should change how you read your own supply book.

The Sentence That Puts You in Scope

Most people who buy and sell industrial chemistry will scroll past a notice with "essential medicines" in the title. Read one sentence of the executive summary before you do.

"Information is requested from qualified manufacturers within the pharmaceutical, chemical, and petrochemical sectors."

All three sectors, written into the ask on purpose. And the reason sits in the third tier of the request: key starting materials, which is ordinary commercial organic chemistry with a regulatory label on it.